Literature DB >> 7826985

Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.

C Häkel1, Y Ueda, H Tsuchya, A Herrera, S Blasius, A Roessner.   

Abstract

The concentrations of the plasminogen activators u-PA and t-PA as well as the inhibitor PAI-1 were studied immunohistochemically in 35 osteosarcoma specimens compared to 15 Ewing's sarcomas and various other bone lesions. The immunoreactivities of plasminogen activators in osteosarcoma specimens were significantly higher than PAI-1. Biochemically in cell cultures and immunohistochemically in the pathological specimens of the osteosarcomas u-PA was the dominant antigen, all factors showing a generally strong reactivity. Here a relation to the malignancy and invasivity of the tumors could be seen, which was comparable to the results in other tumors. This correlation, however, could not be detected in Ewing's sarcomas. On the whole low immunoreactivity of all enzymes, and of u-PA in particular, could be seen. In comparison in some benign lesions (fibrous dysplasias, aneurysmal bone cysts) the immunohistochemical reactions were distinctly stronger. Dominant antigens did not exist in Ewing's sarcomas. In all mesenchymal tumors studied the immunohistochemical localisation and concentration of the antigens showed a definite correlation with their histological differentiation. Chondroblastic differentiations in different tumors (chondrosarcomas, enchondromas, chondroblastic osteosarcomas) or chondroid parts were always negative for both activators and the inhibitor, especially in their central parts. Here, the biological malignancy was not decisive for the result.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826985

Source DB:  PubMed          Journal:  Zentralbl Pathol        ISSN: 0863-4106


  3 in total

1.  Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.

Authors:  Crispin R Dass; Anne P W Nadesapillai; Daniel Robin; Monique L Howard; Jane L Fisher; Hong Zhou; Peter F M Choong
Journal:  Clin Exp Metastasis       Date:  2006-04-29       Impact factor: 5.150

2.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.

Authors:  Liliana Endo-Munoz; Na Cai; Andrew Cumming; Rebecca Macklin; Lilia Merida de Long; Eleni Topkas; Pamela Mukhopadhyay; Michelle Hill; Nicholas A Saunders
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.